Morgan Stanley stays bullish on US stocks despite Middle East tensions, sees healthcare as best defensive bet

Morgan Stanley reaffirmed a bullish 6–12 month view on US equities despite renewed Middle East tensions, citing analysis of 22 geopolitical episodes since 1950 that showed S&P 500 average returns of 2%, 6% and 8% at one, six and 12 months respectively. The bank says a sustained oil shock — roughly a 75–100% year‑on‑year rise — would be required to materially threaten the expansion; current crude is only modestly positive Y/Y. On AI, MS finds limited market exposure (most affected stocks = ~13% of S&P cap) and that 30% of its classified AI adopters reported quantifiable benefits in Q4 (vs 16% a year earlier), with banks, consumer finance and payments seen as net beneficiaries. For defensive positioning it prefers healthcare over consumer staples, citing valuation in the bottom 20%, near‑record low S&P weight, rising earnings revisions and increased 13F flows into the sector; MS also expects two Fed cuts in June and September, which it views as supportive for healthcare and biotech valuations.

Analysis

Market structure: Winners are large-cap healthcare (pharma + late-stage biotech M&A targets), payments (V, MA) and select banks (JPM, BAC) that can monetise AI; losers are richly priced consumer staples and services-only software where disruption risk is concentrated. Oil is the key system-level risk — Morgan Stanley’s >75–100% YoY oil shock threshold implies markets are resilient to modest geo-tension; only a sustained WTI spike to ~$120–150 would reprice growth and rates materially. Cross-asset: two Fed cuts (Jun, Sep) implied by MS points to steeper bond rallies, lower USD and compressed equity discount rates — helping healthcare/biotech; equity vols should fall but oil vol would rise on geopolitical escalation.

Risk assessment: Tail risks include (1) rapid oil >+75% YoY (WTI >$120 for 4+ weeks) triggering stagflation, (2) large biotech trial failures/regulatory crackdowns, and (3) AI regulatory or data-privacy shocks that hit payment and services revenue. Immediate (days): headline-driven spikes in oil/vol; short-term (weeks/months): positioning unwinds around CPI/Jobs and Fed guidance; long-term (quarters): earnings dispersion from AI winners widens — forward EPS growth will separate winners as in 2007 iPhone analog. Hidden dependencies: healthcare rally depends on rate-cut delivery and M&A financing; banks’ AI gains are revenue-mix sensitive and vulnerable to margin compression post-cut.

Key Decisions for Investors

• Establish a 2–3% portfolio long in healthcare via XLV using debit call spreads expiring in June and September (buy nearer-the-money calls, sell higher strikes) to capture rate-cut and M&A re-rate while limiting premium paid.
• Add 1–2% positions in large-cap pharma: buy PFE and MRK (0.5–1% each) for defensive EPS, yield and takeover optionality; trim if either announces major trial failure or if Fed delays June cut beyond July.
• Implement a relative-value pair: long XLV vs short XLP 1:1 notional sized 1–2% portfolio to exploit healthcare’s bottom-20% valuation vs staples’ run-up; rebalance if spread narrows by >25% or XLP underperforms by >5% in 30 days.
• Buy 12–18 month LEAPS on Visa (V) or Mastercard (MA) equal to 1–2% portfolio each to capture AI-driven revenue mix gains; prefer long-dated calls over stock exposure if volatility premium is <25%.
• Put an oil tail hedge in place: purchase a WTI call spread (e.g., strikes that pay if WTI averages >$120 over a 2–4 week window) sized to cap portfolio drawdown to <3% if geopolitics pushes oil >+75% YoY; remove hedge if WTI stays <+$20 YoY for 60 days.